DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 Conference

Rhea-AI Summary

DiamiR Biosciences and Aptorum Group (NASDAQ: APM) announced two poster presentations accepted for the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, Dec 1–4, 2025 in San Diego and online. The posters focus on brain-enriched and inflammation-associated microRNAs as plasma epigenetic biomarkers to classify cognitively unimpaired, MCI, and AD participants and to characterize stages of neurodegeneration.

Presentations occur in the Clinical Trials: Biomarkers session on Dec 3, 2025 (7:15 AM–5:30 PM PST) at the Hilton San Diego Bayfront; poster #225 was conducted with NYU ADRC (grant P30AG066512) and poster #240 with UPenn ADRC. Studies were funded by NIA SBIR grant R44AG044860.

NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announce two poster presentations at the 18^th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, taking place December 1-4, 2025, in San Diego, CA, and online. The presentations will highlight the potential of brain-enriched and inflammation-associated microRNAs as epigenetic biomarkers of neurodegeneration.

Details of the presentations include:

Session.  Clinical trials: Biomarkers, including plasma

Date/Time. Wednesday, December 3^rd, 2025; 7:15 A.M. – 5:30 P.M. PST

Venue. Hilton San Diego Bayfront, San Diego, CA

Poster #225: Developing microRNA classifiers enriched in brain and associated with inflammation in plasma samples to classify Cognitively Unimpaired, MCI, and AD study participants. This work was conducted in collaboration with the New York University (NYU) Alzheimer’s Disease Research Center (ADRC) and NYU ADRC’s grant #P30AG066512 contributed to supporting patient recruitment for the study.

Poster #240: Characterization of stages of neurodegeneration using circulating brain-enriched and inflammation associated microRNAs. This work was conducted in collaboration with the University of Pennsylvania Alzheimer’s Disease Research Center.

The studies were funded by the Small Business Innovation Research (SBIR) Grant #R44AG044860 from the National Institute on Aging (NIA) of the National Institutes of Health.

About CTAD

The Clinical Trials on Alzheimer’s Disease (CTAD) Conference, established in 2008, has become a cornerstone event in Alzheimer’s disease (AD) clinical research. Designed by and for AD researchers, CTAD’s mission is to create a platform that prioritizes substantive, clinical research-focused dialogue and collaboration. By fostering an intimate and collegial environment, CTAD has gained a reputation for facilitating impactful international collaborations and advancing the global AD research agenda. CTAD25 will build on the momentum of previous years, reflecting the rapid advancements in Alzheimer’s disease diagnostics and therapeutics that make this field one of the most dynamic in medical research today. The CTAD scientific program is underpinned by a rigorous peer-review abstract selection process, ensuring the presentation of high-quality research that drives the field forward.

Merger between Aptorum Group and DiamiR Biosciences

As was previously announced on July 16, 2025, Aptorum Group and DiamiR entered into a definitive agreement for an all-stock merger transaction. As a result of this transaction, which remains subject to stockholder approval of both companies and customary closing conditions, DiamiR will become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger. The transaction is expected to close in the first quarter of 2026.

About Aptorum Group

Aptorum Group Limited (Nasdaq: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. For more information, please visit the company’s website at www.aptorumgroup.com.

About DiamiR

DiamiR Biosciences is a private molecular diagnostics company focused on developing and commercializing minimally invasive tests offered through its CLIA-certified, CAP-accredited laboratory for early detection and monitoring of brain health conditions and other diseases in clinical trials and clinical practice settings. DiamiR’s proprietary platform technology, protected by over 50 issued patents worldwide, is based on quantitative analysis of organ-enriched, including brain-enriched and inflammation-associated, microRNA signatures in plasma for screening, patient stratification, as well as disease progression and treatment monitoring. In addition, DiamiR offers protein and genetic biomarker analyses. DiamiR collaborates with leading academic centers, disease foundations, and biopharma companies. For more information, please visit the company's website at www.diamirbio.com and connect with DiamiR on LinkedIn.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often use words such as “believe,” “may,” “will,” “estimate,” “target,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “propose,” “plan,” “project,” “forecast,” “predict,” “potential,” “seek,” “future,” “outlook,” and similar variations and expressions. Forward-looking statements are those that do not relate strictly to historical or current facts. Examples of forward-looking statements may include, among others, statements regarding the consummation and closing of the proposed merger, the satisfactory completion of all conditions to the merger, the shareholder’s approval necessary for the issuance of shares in the merger and re-domestication of Aptorum, Aptorum’s and DiamiR’s  ability to successfully operate its business and provide value to stockholders after completion of the merger, Aptorum’s and DiamiR’s future financial, business and operating performance and goals; annualized recurring revenue and customer retention; ongoing, future or ability to maintain or improve its financial position, cash flows, and liquidity and its expected financial needs; potential financing and ability to obtain financing; acquisition strategy and proposed acquisitions and, if completed, their potential success and financial contributions; strategy and strategic goals, including being able to capitalize on opportunities; expectations relating to Aptorum’s and DiamiR’s industry, outlook and market trends; total addressable market and serviceable addressable market and related projections; plans, strategies and expectations for increasing revenue and executing growth initiatives. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity and development of the industries in which Aptorum and DiamiR operate may differ materially from those made in or suggested by the forward-looking statements. Therefore, investors should not rely on any of these forward-looking statements. Factors that may cause actual results to differ materially include changes in the markets in which Aptorum and DiamiR operate, the financial markets, economic, business and regulatory and other factors, such as Aptorum’s and DiamiR’s ability to execute on their strategies. More detailed information about risk factors can be found in the Aptorum’s Annual Report on Form 20-F under the heading “Risk Factors,” and in other reports filed by the Aptorum, including reports on Form 6-K and the registration statement on Form S-4 filed with the SEC on October 6, 2025. Aptorum and DiamiR do not undertake any duty to update forward-looking statements after the date of this press release.

No Offer or Solicitation

This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any proxy, consent, authorization, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made, except by means of a prospectus meeting the requirements of the U.S. Securities Act of 1933, as amended.

Additional Information About the Proposed Merger and Where to Find It

In connection with the merger, Aptorum filed a current report on Form 6-K to disclose additional details about the merger and a registration statement on Form S-4 with the SEC, and will mail notices of shareholders meeting and other relevant documents to its shareholders. Investors and security holders of Aptorum are advised to read the Form S-4, and amendments thereto, the notice to shareholders, and amendments thereto, in connection with Aptorum’s solicitation of proxies for its shareholder' meeting to be held to approve the proposed merger because the notice to shareholders will contain important information about the transaction and the parties to the transaction, and stockholders are urged to read the proxy statement/prospectus and the other relevant materials when they become available before making any voting or investment decision with respect to the merger and related proposals. The notices to shareholders will be mailed to Aptorum’s shareholders as of a record date to be established for voting on the transactions. Shareholders will also be able to obtain copies of the notice, without charge, once available, at the SEC's website at www.sec.gov or by directing a request to: Ian Huen, telephone: +44 20 80929299.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.  A copy of Aptorum's registration statement on Form S-4 can be viewed on the SEC's website.

Participants in the Solicitation

Aptorum Group, DiamiR and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from stockholders in connection with the merger. Information about Aptorum's directors and executive officers including a description of their interests in Aptorum is included in Aptorum’s most recent Annual Report on Form 20-F, including any information incorporated therein by reference, as filed with the SEC. Additional information regarding these persons and their interests in the transaction are included in the proxy statement/prospectus relating to the merger that was filed with the SEC in a registration statement on Form S-4 on October 6, 2025. These documents can be obtained free of charge from the sources indicated above.

For more information, please contact: 

DiamiR Biosciences

Alidad Mireskandari, PhD
203-570-8275
amireskandari@diamirbio.com  

Aptorum Group Limited

Investor Relations Department
investor.relations@aptorumgroup.com
+44 20 80929299

FAQ

When will Aptorum Group (APM) present at CTAD 2025?

Aptorum Group will have posters in the Biomarkers session on Dec 3, 2025 between 7:15 AM–5:30 PM PST.

What topics will Aptorum Group (APM) cover in the CTAD 2025 posters?

The posters cover brain-enriched and inflammation-associated microRNAs as plasma epigenetic biomarkers for classifying Cognitively Unimpaired, MCI, and AD and for staging neurodegeneration.

What are the poster numbers for Aptorum Group (APM) at CTAD 2025?

The posters are #225 (microRNA classifiers) and #240 (staging neurodegeneration).

Where and how can investors or researchers view Aptorum Group (APM) CTAD 2025 presentations?

The CTAD conference is in San Diego (Hilton San Diego Bayfront) and online; posters will be available at the conference on Dec 3, 2025 and via CTAD’s online platform if provided.

Who collaborated on the research presented by Aptorum Group (APM) at CTAD 2025?

Poster #225 was conducted with NYU Alzheimer’s Disease Research Center (grant P30AG066512) and poster #240 with the University of Pennsylvania ADRC.

What funding supported the Aptorum Group (APM) CTAD 2025 studies?

The studies were funded by the NIA SBIR grant R44AG044860 from the National Institute on Aging.